Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Blue Note Therapeutics
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Stage I-III breast cancer or Stage I-III NSCLC who are currently in active treatment or have completed initial cancer directed treatments (surgery, radiation, chemotherapy) within the past 3 months;
Are experiencing at least moderate anxiety (GAD-7 \>10) or mild-to-moderate depression (PHQ-8 score 5-11);
Are fluent in English; and
Have access to smartphone, or tablet capable of running iOS or Android software.
You may not be if
Previous history of cancer;
\<2-yr survival prognosis as determined by treating clinician;
Currently participating in investigative CBT trial for treatment of anxiety or depression;
Participant is unable to complete training, has cognitive deficits, more severe psychiatric conditions, lack of access to internet accessible device or psycho-social conditions (e.g., other social conditions, that would interfere with adherence to self-directed care), such that in investigator's opinion the participant would be unable to complete the study;
Recently completed use of Blue Note Therapeutics Covid Cancer Care Program or other Blue Note Therapeutics-sponsored study; and
PHQ-9 Q9 response \>0 AND Columbia Suicide Severity Risk Scale (or equivalent) score of Category 2- "suicidal ideation" at screening.
Clareo Health | Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment
